ELEKTA AND SWEDFUND INVEST IN CANCER CARE IN DEVELOPING COUNTRIES

ELEKTA AND SWEDFUND INVEST IN CANCER CARE IN DEVELOPING COUNTRIES

The medical technology company Elekta has formed an investment company, Global
Medical Investments "GMI", with Swedfund International AB for financing and
establishment of cancer care projects in developing countries.

Global Medical Investments, GMI, will invest, develop and support the
establishment of cancer management programs in developing countries across the
world in cooperation with local healthcare providers and partners.

“We are very pleased that we, in cooperation with Swedfund, have been able to
establish this investment vehicle for the development of cancer care programs in
the most needing countries in the world. Our expertise in cancer and cancer
management, combined with Swedfund's long experience of successful development
investments in third world countries, provide a unique opportunity to support
the development of advanced health care in many developing countries”,  says Dr
Laurent Leksell, founder and Executive Director of Elekta AB.

Through GMI, Swedfund and Elekta will be able to provide technology and
competence for first class cancer management. Elekta and Swedfund will each
invest up to USD 10 M in GMI. Through this initiative Elekta will also
strengthen its presence in countries where the company has limited business
activities. 

GMI is currently in the final stage of development of the first sophisticated
radiotherapy center in Accra, Ghana. This is developed in close collaboration
with Scandinavian Care Projects AB, which is leading this project, and with
local partners. The cancer center is expected to initiate treatment in the first
half of 2010, and will give the people in Ghana access to effective and cost
efficient cancer treatment with Elekta's latest technology.

“We believe that this investment, with Swedish expertise in health care and
medical technology, will contribute to increased availability of advanced
medical care. Swedfund participated in the financing of the first GammaKnife in
Africa, which is located in Egypt, and we are very pleased by this extended
cooperation which we believe will lead to many new cancer centers in developing
countries”, says Björn Blomberg, Managing Director of Swedfund.

******

For further information, please contact:

Stina Thorman, Investor Relations, Elekta AB
Tel: +46 8 587 257 34, +46 70 778 60 10, e-mail: stina.thorman@elekta.com   

Maria Lannér, Director Communications, Swedfund
Tel: +46 8 725 94 17, +46 708 186808, e-mail: maria.lanner@swedfund.se

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care. Stretching the boundaries of science
and technology, providing intelligent and resource-efficient solutions that
offer confidence to both healthcare providers and patients, Elekta aims to
improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group. Elekta
employs around 2,500 employees globally. The corporate headquarter is located in
Stockholm, Sweden, and the company is listed on the Nordic Exchange under the
ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


About Swedfund
Swedfund offers risk capital and competence for investment in Africa, Asia,
Latin America and Eastern Europe (non-EU members). Swedfund's vision is to
contribute to the development of profitable companies and thereby stimulate
sustainable economic development in poor countries and stimulate business
opportunities for Swedish companies. All decisions regarding investments are
based solely on business principles. In 2008 Swedfund had a balance sheet total
of about SEK 2.8 B and is owned by the Swedish state.